Q-omics provides the consensus-scored CDR2L profile across patient tissues and cancer cell-line models. CDR2L expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, CDR2L is differentially expressed in 17, with the highest sampling consensus in HNSC. Additionally, CDR2L RNA expression shows 18,041 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and HNSC as cancer lineages where CDR2L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDR2L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDR2L survival associations across molecular data types. CDR2L RNA expression shows survival associations in the most cancer types (27), followed by mutation status (3) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDR2L RNA expression–survival associations across cancer types. High CDR2L expression shows unfavorable associations in ACC, MESO, COAD, HNSC, BLCA and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for CDR2L RNA expression.
This table summarizes CDR2L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for CDR2L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDR2L shows lower tumor expression in KICH and higher tumor expression in HNSC, COAD, KIRP, BLCA and THCA. The HNSC box plot shows higher CDR2L RNA expression in tumor versus normal tissue (log2 FC = +1.652, t-test p < 0.001).
This table shows molecular features associated with CDR2L in patient tissues and cancer cell lines. In patient samples, CDR2L shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, CDR2L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
